Systemic Lupus Erythematosus
Data from a Phase 2 trial of baricitinib for the treatment of SLE supporting the Fast Track designation were published in The Lancet and presented at the European Congress of Rheumatology earlier this year.
Researchers described 8 patients with antimalarial-induced cardiomyopathy in a defined systemic lupus erythematosus cohort.
Researchers observed comparable long-term outcomes between patients with late- and early-onset lupus nephritis.
Data support the clinical efficacy of low-dose leflunomide combined with prednisone for the treatment of proliferative lupus nephritis.
Intrauterine fetal death may be an early sign of antiphospholipid syndrome in pregnant women.
Risk factors for psychosis in SLE included male sex and African ancestry.
Researchers examined the role of CB-CAPs for diagnosis and monitoring of pediatric-onset SLE.
Investigators evaluated the immunogenicity of pneumococcal vaccination in children with systemic lupus erythematosus.
A positive direct Coombs test in the absence of hemolytic anemia may be a useful biomarker for assessing disease activity in systemic lupus erythematosus.
High and low HCQ levels were associated with preterm birth and disease activity in SLE.
Long-term treatment of SLE with belimumab with standard of care resulted in sustained benefits in patient fatigue and health-related quality of life.
A strong association between antiphospholipid positivity and first-time MI may represent a risk factor for myocardial infarction.
Investigators sought to define the clinical association of clinical and imaging definitions of synovitis in patients with SLE with musculoskeletal symptoms.
Researchers identified SERPINA3 as a potential urine biomarker to quantify lupus nephritis.
Researchers sought to determine whether a cardiovascular magnetic resonance protocol may be useful for early diagnosis of heart disease in patients with systemic lupus erythematosus.
Recent evidence links specific bacterial, viral infections, and vaccination to the development of APS, but these associations are not clear-cut.
Patients with SLE who experienced high pain levels and had a visit to the emergency department the previous year were more likely to use opioids.
Experts at the 2018 ACR/ARHP Annual Meeting discuss whether hydroxychloroquine dosing should be more than 5 mg/kg in patients with systemic lupus erythematosus.
Results from a phase 2 study suggest that ustekinumab might be an effective therapy in systemic lupus erythematosus.
Therapeutic drug monitoring may be useful to help clinicians assess nonadherence in patients with SLE.
Data revealed an association between myasthenia gravis and autoimmune rheumatic diseases.
Patients with systemic lupus erythematosus have a high risk for postoperative complications and mortality following major surgery compared with patients without SLE.
The initiation of statin therapy is associated with reduced overall mortality in patients with systemic autoimmune rheumatic diseases.
Patient-reported outcomes are independent predictors of mortality in systemic lupus erythematosus.
Vaccination rates in patients with systemic lupus erythematosus improved significantly after the implementation of a multifaceted intervention at a rheumatology practice.
Over a 5-year period, the drug was well tolerated and associated with significant declines in urinary protein-creatinine ratio and mean prednisolone dose.
Childhood-onset SLE has major effects on quality of life in adulthood.
The use of validated disease activity and damage metrics is important in the assessment of SLE.
Cigarette smoking was associated with an increased SLE risk and alcohol consumption was associated with decreased SLE risk.
Prolonged antimalarial therapy and persistent creatine phosphokinase elevation resulted in an increased risk for abnormal brain natriuretic peptide and cardiac troponin.
Rheumatology Advisor Articles
- Ultrasonography in Gout: Potential Applications for Diagnosis and Patient Monitoring
- Immunogenicity of Golimumab Validated Using Novel Anti-Drug Antibody Detection Assay
- Similar Long-Term Outcomes in Early- vs Late-Onset Lupus Nephritis
- Radiographic Knee OA Not Correlated With Diabetes, Altered Glucose Metabolism
- Serum sRAGE Correlated With Disease Activity in Rheumatoid Arthritis
- Inflammatory Arthritis and the Gut Microbiome: Do Microbes Hold the Key to New Treatments?
- Examining Insurance Complications in the Shared Decision Making Process for Rheumatoid Arthritis
- Smoking Linked to Cognitive Dysfunction in Fibromyalgia
- Patient Education Can Improve Chronic Disease Management
- Health-Enhancing Physical Activity Program Reduces Global Pain in RA
- Chronic Opioid Use Has Doubled Since 2002 Among Patients With RA
- Baricitinib Gets Fast Track Status for Systemic Lupus Erythematosus
- Flaws, Potential Solutions for Physician Incentive Programs Examined
- Metabolic Syndrome, Psoriatic Arthritis Highly Prevalent in Patients With Plaque Psoriasis
- Gene Polymorphisms Predict Response to Tocilizumab, Rituximab in RA